GlassScriptPhysician profile
Brad P Baltz
NPI 1164484614
$25,054.35
in general payments reported to CMS, 2019-2025
79 companies · $4,407 in 2025
The $4,407 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,389 · 2020: $2,873 · 2021: $2,978 · 2022: $3,052 · 2023: $3,445 · 2024: $3,911 · 2025: $4,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,561.89 |
| Education | $200.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,024.77 | 2019-2025 | |
| Pfizer INC. | $1,830.80 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,444.74 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $1,442.62 | 2019-2025 | Imfinzi, Enhertu, Tagrisso |
| Incyte Corporation | $1,239.40 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Celgene Corporation | $1,136.15 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $1,107.02 | 2019-2025 | Adcetris, Tukysa |
| Genentech USA, INC. | $1,054.45 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Genzyme Corporation | $783.76 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $758.11 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Janssen Biotech, INC. | $711.54 | 2019-2025 | Darzalex, Imbruvica, Rybrevant |
| Abbvie INC. | $662.41 | 2019-2025 | Venclexta |
| Lilly USA, LLC | $659.60 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Exelixis INC. | $553.89 | 2019-2025 | Cabometyx |
| Astellas Pharma US INC | $511.76 | 2019-2025 | Padcev, Xospata, Xtandi |
Show all 79 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $469.80 | 2019-2025 | |
| Emd Serono, INC. | $462.33 | 2019-2025 | Bavencio |
| Janssen Pharmaceuticals, INC | $449.79 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $431.81 | 2019-2025 | |
| Daiichi Sankyo INC. | $405.03 | 2019-2025 | Enhertu, Datroway |
| Amgen INC. | $392.69 | 2019-2023 | Lumakras, Kyprolis, Nplate |
| Sumitomo Pharma America, INC. | $377.38 | 2023-2025 | Orgovyx |
| Pharmacyclics LLC, An Abbvie Company | $356.54 | 2019-2023 | Imbruvica, Epkinly |
| Regeneron Healthcare Solutions, INC. | $302.10 | 2022-2025 | Libtayo |
| Array Biopharma INC | $279.13 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Global Blood Therapeutics, INC. | $269.48 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $262.58 | 2019-2025 | Fruzaqla, Iclusig, Ninlaro |
| Puma Biotechnology, INC. | $253.08 | 2019-2024 | |
| Beigene USA, INC. | $246.32 | 2020-2025 | Brukinsa |
| Glaxosmithkline, LLC. | $241.95 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Aveo Pharmaceuticals, INC. | $215.54 | 2021-2025 | Fotivda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.26 | 2020-2025 | Gilotrif |
| Ipsen Biopharmaceuticals, INC | $201.23 | 2022-2025 | Onivyde, Somatuline Depot, Tazverik |
| Gilead Sciences, INC. | $194.77 | 2019-2025 | Trodelvy |
| Tesaro, INC. | $193.63 | 2019 | |
| Myovant Sciences INC. | $188.48 | 2021-2022 | |
| Beone Medicines USA, INC. | $174.39 | 2025 | Brukinsa, Tevimbra |
| Pharmacosmos Therapeutics INC. | $170.42 | 2023-2025 | Monoferric, Cosela |
| Epizyme, INC. | $129.99 | 2020-2022 | |
| Pharmaessentia USA Corporation | $126.31 | 2022-2024 | Besremi |
| Mirati Therapeutics, INC. | $124.36 | 2023-2024 | Krazati |
| Clovis Oncology, INC. | $122.43 | 2019-2020 | |
| Sobi, INC | $121.75 | 2023-2025 | |
| Amag Pharmaceuticals, INC. | $120.38 | 2019-2022 | |
| Adc Therapeutics America, INC. | $117.45 | 2021-2025 | |
| Foundation Medicine, INC. | $92.49 | 2019-2021 | |
| Kite Pharma, INC. | $85.79 | 2022-2023 | Yescarta |
| Rigel Pharmaceuticals, INC. | $84.37 | 2022-2024 | Tavalisse, Rezlidhia |
| Stemline Therapeutics INC. | $83.96 | 2023-2025 | Orserdu |
| Caris Mpi, INC. | $74.07 | 2025 | Mi Cancer Seek |
| Tersera Therapeutics LLC | $69.99 | 2024-2025 | Zoladex |
| Morphosys, US INC. | $69.88 | 2023 | Monjuvi |
| Kyowa Kirin, INC. | $67.38 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $65.61 | 2020-2025 | Qinlock, Romvimza |
| Shield Therapeutics INC | $64.12 | 2025 | |
| G1 Therapeutics, INC. | $58.35 | 2022-2023 | Cosela |
| Dova Pharmaceuticals | $56.89 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $49.70 | 2019 | |
| Servier Pharmaceuticals LLC | $47.61 | 2023-2024 | |
| Coherus Oncology, INC. | $47.27 | 2021-2025 | Loqtorzi |
| Fresenius Kabi USA, LLC | $45.02 | 2025 | Stimufend |
| Legend Biotech USA INC. | $41.38 | 2025 | Carvykti |
| Agios Pharmaceuticals, INC. | $32.91 | 2019-2024 | Pyrukynd |
| Karyopharm Therapeutics INC. | $31.52 | 2023 | Xpovio |
| Alnylam Pharmaceuticals INC. | $31.28 | 2020-2024 | Givlaari |
| Taiho Oncology, INC. | $30.82 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $28.49 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $28.00 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $26.79 | 2019-2020 | |
| Adaptive Biotechnologies Corporation | $25.22 | 2022 | |
| Alexion Pharmaceuticals, INC. | $25.11 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $24.42 | 2019 | |
| Verastem, INC. | $22.75 | 2019 | |
| Azurity Pharmaceuticals, INC. | $21.63 | 2025 | Vivimusta, Danziten |
| Secura Bio, INC. | $21.26 | 2025 | Copiktra |
| Nuvation Bio INC. | $18.52 | 2025 | Ibtrozi |
| Corcept Therapeutics | $18.42 | 2025 | Korlym |
| Geron Corporation | $16.94 | 2025 | Rytelo |
| Acrotech Biopharma INC. | $11.97 | 2022 |
Drugs and devices associated with these payments
Reblozyl $622Enhertu $598Orgovyx $526Keytruda $490Jakafi $376Imfinzi $362Cabometyx $316Tukysa $305Imbruvica $286Lenvima $285Adcetris $285Venclexta $280Libtayo $280Ibrance $278Pluvicto $266Scemblix $262Lynparza $257Brukinsa $245Xtandi $239Padcev $237Sarclisa $228Monjuvi $226Jaypirca $191Elrexfio $172Fotivda $165Polivy $163Fabhalta $156Verzenio $155Tecentriq $153Braftovi $146Gilotrif $142Monoferric $141Onivyde $139Talzenna $132Lorbrena $126Lunsumio $125Darzalex $124Krazati $124Oxbryta $117Fruzaqla $116Epkinly $113Bosulif $112Mektovi $103Besremi $101Trodelvy $98.02Inlyta $97.27Stivarga $96.62Kisqali $95.40Retevmo $93.91Opdivo $85.50Elahere $85.13Welireg $84.78Ojjaara $84.70Orserdu $83.96Xospata $78.31Opdualag $77.51Tasigna $77.04Lutathera $74.11Mi Cancer Seek $74.07Phesgo $73.99Zoladex $69.99Accrufer $64.12Doptelet $63.28Rybrevant $62.66Lumakras $60.62Talvey $59.87Tecvayli $59.87Vonjo $58.47Promacta $57.32Datroway $56.50Alecensa $54.95Vitrakvi $53.72Keytruda Qlex $52.40Akeega $51.86Erleada $51.86Somatuline Depot $48.79Romvimza $48.76Qinlock $48.76Pomalyst $45.06Stimufend $45.02Cosela $44.44Bavencio $43.47Balversa $42.03Carvykti $41.38Jemperli $37.51Zejula $37.51Xofigo $35.00Nubeqa $35.00Tibsovo $34.09Yescarta $32.53Tevimbra $31.68Xpovio $31.52Piqray $30.79Tagrisso $30.62Comirnaty $30.17Ayvakit $29.38Tecentriq Hybreza $29.11Columvi $28.85Iclusig $28.11Loqtorzi $27.64
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Baltz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.